Truncated L1 protein of human papillomavirus type 11
AssigneesXiamen University, Xiamen Innovax Biotech Co., Ltd.
InventorsJun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
Life of this patent
Estimating the term…
Abstract
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
Claims13
A N-terminally truncated HPV11 L1 protein consisting of SEQ ID NO.:
- 2.
A HPV 11 virus-like particle (VLP) comprising a N-terminally truncated HPV11 L1 protein consisting of SEQ ID NO.:
- 2.
A method for producing a N-terminally truncated HPV11 L1 protein consisting of SEQ ID NO.:
- 2, comprising:
- a) expressing a HPV L1 gene encoding the N-terminally truncated HPV L1 protein in an E. coli expression system;
- b) disrupting the E. coli, which has expressed the N-terminally truncated HPV L1 protein, in a solution at a salt concentration of from 100 mM to 600 mM, and isolating the supernatant;
- c) decreasing the salt concentration of the supernatant of b) to from 100 mM to 0, inclusive, by using water or a low salt solution, and collecting a precipitate;
- and
- d) redissolving the precipitation of c) in a solution at a salt concentration of from 150 mM to 2500 mM, adding a reductant to it, and then isolating the resultant solution, wherein the solution contains the N-terminally truncated HPV L1 protein with a purity of at least 50%.
Dependencies are inferred from the claim text.